Matrine inhibits the proliferation of prostate cancer cells and the activity of androgen receptor.
- Author:
Ke CHEN
1
;
Zhi-Quan HU
;
Tao WANG
;
Jun-Li GUO
;
Hui GUO
;
Zhang-Qun YE
Author Information
- Publication Type:Journal Article
- MeSH: Alkaloids; pharmacology; Blotting, Western; Cell Cycle; drug effects; Cell Line, Tumor; Cell Proliferation; drug effects; Cell Survival; drug effects; Dose-Response Relationship, Drug; Flow Cytometry; Humans; Male; Prostatic Neoplasms; metabolism; pathology; Quinolizines; pharmacology; Receptors, Androgen; metabolism
- From: National Journal of Andrology 2008;14(8):719-722
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo study the inhibitory effect of matrine on the proliferation of the prostate cancer cell line LNCaP and the expression of the androgen receptor (AR).
METHODSLNCaP cells were treated with matrine at the concentration of 0.5, 1.0, 1.5, 2.0 and 3.0 g/L for 12, 24 and 36 hours, the cell growth activity determined by MTT colorimetry and trypan blue staining at 36 hours, the cell cycle changes detected by flow cytometry and the expression of AR by Western blot at 24 hours.
RESULTSMatrine suppressed the in vitro growth of the androgen-sensitive prostate cancer cell line LNCaP in a time- and dose-dependent manner, blocked the cell cycles in the G2/M phase and decreased the expression of AR in the cell line in a dose-dependent manner (P < 0.01).
CONCLUSIONMatrine can significantly inhibit the in vitro growth of NCaP cells by down-regulating the expression of AR and blocking cell cycles.
